LX2006 for the Treatment of FA Cardiomyopathy: Received clearance of CTA in Canada for LX2006 for the treatment of FA cardiomyopathy and activated the first clinical trial site for the SUNRISE-FA Phase 1/2 clinical trial outside of the United States.
LX2006 for the treatment of Friedreich’s ataxia cardiomyopathy: Interim data readout in mid-2024
